View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2014

BioLineRx gets US patent covering use of BL-8040 in immunotherapy

Israel-based clinical-stage biopharmaceutical firm BioLineRx has announced that an Issue of Notification has been received from the US Patent and Trademark Office (USPTO) for US Patent No. 8,663,651.

By mohamed elseman

The patent includes claims to protect the use of a clinical-stage drug candidate BL-8040’s composition for improving immune responses to an antigen, such as a tumor-associated antigen.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

The issued patent has a term extending to October 2029 and is part of BL-8040’s expanding patent portfolio, which includes 13 issued patents and 25 patent applications pending worldwide, providing a strong intellectual property estate around BL-8040.

BioLineRx chief executive officer Kinneret Savitsky said the company is happy with this newly issued patent for BL-8040, which further strengthens the patent position it has for its leading oncology program.

"We view BL-8040 as a platform for multiple oncological and hematological indications, and robust patent protection provides us with the foundation to pursue these multiple indications for the BL-8040 platform," Savitsky said.

"BL-8040 is currently undergoing a Phase 2 trial for the treatment of acute myeloid leukemia and is expected to enter a Phase 1 trial for stem cell mobilization in the 2nd quarter of 2014."We expect top-line results for both of these clinical studies towards the end of the year or early next year."

BL-8040, which is a short peptide that functions as a high-affinity antagonist for CXCR4, is indicated for the treatment of acute myeloid leukemia, as well as other hematological indications.

CXCR4 is a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival.

It is over-expressed in over 70% of human cancers and its expression often correlates with disease severity.

Currently, BL-8040 is undergoing Phase II trial for acute myeloid leukemia (AML) and is expected to start Phase I trial in stem cell mobilization in the second quarter of 2014.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology